David W. Stroman, SVP, Ophthalmic Product Devt at NovaBay Pharmaceuticals, Inc. (NBY), bought 10,000 shares at $0.66 ($7K) on 2014-12-12, disclosed to the SEC on 2014-12-16.
Open-market purchase of $7k NBY by SVP, Ophthalmic Product Devt. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.